Genmab A (GMAB) Return on Capital Employed (2020 - 2026)

Genmab A (GMAB) reported Return on Capital Employed of 10.37% for Q1 2026, down 52.74% quarter-over-quarter from 21.94% in Q3 2025.

Genmab A (GMAB) Return on Capital Employed (2020 - 2026) Analysis & Trends

Genmab A has reported Return on Capital Employed for 3 years, with the latest figure at 10.37% in Q1 2026.

For the quarter ending Q1 2026, Return on Capital Employed changed N/A year-over-year to 10.37%; the trailing twelve-month figure through Mar 2026 stood at 10.37% (changed N/A YoY), and the FY2025 full-year result was 12.83%, changed N/A from the prior year.
Return on Capital Employed for Q1 2026 stood at 10.37%, down from 21.94% in the prior quarter.
The five-year high for Return on Capital Employed was 21.94% in Q3 2025, with the low at 10.37% in Q1 2026.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	ROCE (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-	450.31%
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn	51.73%
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-	-107.40%
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn	21.10%
9	Abivax	91.96 Bn	91.96 Bn	-	-50.43%
10	Genmab A	48.57 Bn	47.05 Bn	831.00 Mn	10.37%

Download Data